Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; Phase III clinical trial in combination with rituximab...
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks.
Target Price
The average target price of ADCT is 7.8 and suggests 80% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
Buy
Sell